On Oct. 3, 2023, Novavax announced that it’s COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Immediately upon authorization, Novavax’s vaccine had also been included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on September 12, 2023.